outcome of meeting
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals reported FY2026 consolidated revenue from operations of Rs 3,82,167 lakhs, up 1.93% from Rs 3,74,921 lakhs in the prior year. Profit before tax grew 11.6% to Rs 1,40,601 lakhs (vs Rs 1,25,988 lakhs), and profit after tax rose 11.7% to Rs 1,03,598 lakhs (vs Rs 92,758 lakhs). The company reported exceptional items credit of Rs 2,062 lakhs, primarily from sale of a non-operational land site (Rs 1,798 lakhs) and surplus residential properties (Rs 264 lakhs). PAT growth of ~11.7% did not meet the 25% threshold. EBITDA margin compressed from 33.5% to ~32.5% despite higher absolute EBITDA. An unmodified audit opinion was issued by Deloitte Haskins & Sells LLP. The Board recommended a final dividend of Rs 57 per share (up from Rs 42), with record date 29th May 2026.
Revenue growth was modest at ~2%, below expectations, though PAT growth of ~12% was driven by higher other income and lower tax rate. The margin compression signals cost pressures. The dividend increase is positive for income-oriented investors.